Lisata Therapeutics
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
110 Allen Rd Ste 2, Basking Ridge, New J...Phone Number
(908) 842-0100Website
www.lisata.comRevenue
<$5 MillionStock Symbol
LSTAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Explore more
Lisata Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lisata Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Lisata Therapeutics has new funding data
Click to see if Lisata Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lisata Therapeutics
Product Launch: Get notified when Lisata Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Lisata Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Lisata Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Lisata Therapeutics recently announced quarterly report
Check out if Lisata Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Lisata Therapeutics
Find 3 more new buyers
Compare Similar Companies to Lisata Therapeutics
Compare insights from companies similar to Lisata Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Lisata Therapeutics
<$5M
11-50
Public
<$5M
1980
TI
Tariq ImamSenior Vice President, Business Development, Operations and General Counsel
Company Profile Activity
Activity Insights
Lisata Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lisata Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lisata Therapeutics.
Lisata Therapeutics financials insights
Gather financial insights about Lisata Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$2.2M
Lisata Therapeutics Tech Stack
A closer look at the technologies used by Lisata Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings
Lisata Therapeutics News & Media
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)
BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, March 9, 2026 /PRNewswire/ -- Ademi LLP is investigating Lisata (NASDAQ: LSTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Kuva Labs Inc. Click here to learn how to join our investigation and obtain additional...Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lisata Therapeutics
Sign Up For FreeTo access detailed company insights
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancr... Read More
